Motor Cortex Reward Signaling in Parkinson Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00558766|
Recruitment Status : Completed
First Posted : November 15, 2007
Last Update Posted : July 2, 2017
The brain releases signals to mark rewards for certain behavior. Some medications for Parkinson disease (PD) can cause some patients to engage in compulsive behavior, possibly because the medications affect this reward system.
By using transcranial magnetic stimulation (TMS), researchers can study brain activity when an individual receives a reward.
To learn how the brains of people with PD behave when rewarded.
To learn whether two common Parkinson medications (levodopa and pramipexole) change this behavior.
To compare reward signals in the brains of healthy volunteers with reward signals in the brains of people with PD.
Women between 50 and 80 years of age and men between 45 and 80 years of age.
Participants will be divided into healthy volunteers and volunteers who have mild to moderate PD.
Prescreening will consist of a neurological examination and a series of questions about gambling habits and drug and alcohol use.
Participation in a TMS study involving a computer game simulation of a slot machine:
- Before the simulation, participants will receive TMS to establish a baseline response rate.
- During the simulation, participants will play a game in which they will receive real money.
TMS will be administered to each patient under three different conditions:
- TMS administered when patients have not taken any Parkinson medication.
- TMS administered after patients have taken levodopa.
- TMS administered after patients have taken pramipexole....
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||35 participants|
|Official Title:||Motor Cortex Reward Signaling in Parkinson Disease|
|Study Start Date :||November 8, 2007|
|Study Completion Date :||June 13, 2011|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00558766
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|